---
layout: default
title: Benazepril
description: "Benazepril çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 5 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 30
evidence_level: L4
indication_count: 5
---

# Benazepril

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>5</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Benazeprilï¼šå¾åŸç™¼æ€§é«˜è¡€å£“åˆ°æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Benazepril å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Benazepril æ˜¯ ACE æŠ‘åˆ¶åŠ‘ï¼Œç”¨æ–¼æ²»ç™‚é«˜è¡€å£“ï¼ŒTxGNN é æ¸¬å…¶å°æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“å’Œæƒ¡æ€§é«˜è¡€å£“è…ç—…æœ‰æ•ˆï¼Œä½†éœ€æ³¨æ„æ­¤é¡ç–¾ç—…ä½¿ç”¨ ACE æŠ‘åˆ¶åŠ‘çš„ç¦å¿Œç—‡ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

ï¼ˆè¦‹ä¸‹æ–¹è©³ç´°åˆ†æï¼‰



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. malignant renovascular hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.65%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. malignant hypertensive renal disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.65%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pulmonary hypertension with unclear multifactorial mechanism</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.60%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary hypertension owing to lung disease and/or hypoxia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.60%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33862277/" target="_blank">33862277</a></td><td>2021</td><td>Article</td><td>Ageing research reviews</td><td>Hypoxia and brain aging: Neurodegeneration or neuroprotection?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37328448/" target="_blank">37328448</a></td><td>2023</td><td>Article</td><td>Advanced science (Weinheim, Ba</td><td>N4-Acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39841808/" target="_blank">39841808</a></td><td>2025</td><td>Article</td><td>Science translational medicine</td><td>Hypoxia as a medicine.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28972206/" target="_blank">28972206</a></td><td>2017</td><td>Article</td><td>Nature reviews. Immunology</td><td>Regulation of immunity and inflammation by hypoxia in immunological niches.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34618295/" target="_blank">34618295</a></td><td>2022</td><td>Article</td><td>Metabolic brain disease</td><td>Cognitive impairment caused by hypoxia: from clinical evidences to molecular mec...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31706510/" target="_blank">31706510</a></td><td>2019</td><td>Article</td><td>Trends in cancer</td><td>DUBs, Hypoxia, and Cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21328446/" target="_blank">21328446</a></td><td>2011</td><td>Article</td><td>Journal of cellular biochemist</td><td>Hypoxia-mediated biological control.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40347693/" target="_blank">40347693</a></td><td>2025</td><td>Article</td><td>Redox biology</td><td>Hypoxia in multiple sclerosis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34535359/" target="_blank">34535359</a></td><td>2021</td><td>Article</td><td>Clinical oncology (Royal Colle</td><td>Therapeutic Modification of Hypoxia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11172576/" target="_blank">11172576</a></td><td>2000</td><td>Article</td><td>Respiratory care clinics of No</td><td>Mechanisms of hypoxemia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24557798/" target="_blank">24557798</a></td><td>2014</td><td>Article</td><td>Journal of applied physiology </td><td>Translation in progress: hypoxia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4585366/" target="_blank">4585366</a></td><td>1973</td><td>Article</td><td>Revista medica de Chile</td><td>[Cerebral hypoxia].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36100192/" target="_blank">36100192</a></td><td>2022</td><td>Article</td><td>Journal of controlled release </td><td>Research progress on tumor hypoxia-associative nanomedicine.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2164797/" target="_blank">2164797</a></td><td>1990</td><td>Article</td><td>Annales francaises d&#x27;anesthesi</td><td>[Postanoxia encephalopathies].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37915135/" target="_blank">37915135</a></td><td>2023</td><td>Article</td><td>BMB reports</td><td>Regulation of CMGC kinases by hypoxia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30423905/" target="_blank">30423905</a></td><td>2018</td><td>Article</td><td>International journal of molec</td><td>Hypoxic Microenvironment and Metastatic Bone Disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8817697/" target="_blank">8817697</a></td><td>1996</td><td>Article</td><td>Progress in neurobiology</td><td>Hypoxia and brain development.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18345017/" target="_blank">18345017</a></td><td>2008</td><td>Article</td><td>Cell death and differentiation</td><td>Hypoxia-inducible factor: roles in development, physiology, and disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27146279/" target="_blank">27146279</a></td><td>2017</td><td>Article</td><td>Cephalalgia : an international</td><td>Hypoxic mechanisms in primary headaches.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28493839/" target="_blank">28493839</a></td><td>2017</td><td>Article</td><td>Oncotarget</td><td>Hypoxia inducible factors in hepatocellular carcinoma.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. Braddock syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.44%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|----------|----------|------|--------------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬056647è™Ÿ | ç´“å¿ƒè† å›Š | è† å›ŠåŠ‘ | æ±ç”Ÿè¯è£½è—¥ | 2026/07/21 |
| è¡›ç½²è—¥è£½å­—ç¬¬057325è™Ÿ | å£“è«¾æœ¬éŒ  | éŒ åŠ‘ | å°ç£æ±æ´‹è—¥å“ | 2027/08/10 |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬025881è™Ÿ | é¹½é…¸è²é‚£æ™®åˆ© | åŸæ–™è—¥ | é´»å‚‘è—¥å“ | 2027/12/28 |
| è¡›ç½²è—¥è£½å­—ç¬¬046742è™Ÿ | è«¾å£“éŒ  | éŒ åŠ‘ | æ±ç”Ÿè¯è£½è—¥ | 2029/12/24 |
| è¡›éƒ¨è—¥è£½å­—ç¬¬059395è™Ÿ | å¯å¾—å¯§è†œè¡£éŒ  | è†œè¡£éŒ  | ä¸­åœ‹åŒ–å­¸è£½è—¥ | 2026/12/09 |

## å®‰å…¨æ€§è€ƒé‡
- **Moderate äº¤äº’ä½œç”¨**ï¼š
  - Hydrocortisoneï¼šå¯èƒ½é™ä½é™å£“æ•ˆæœ
  - Alogliptin ç­‰é™è¡€ç³–è—¥ï¼šå¯èƒ½å¢å¼·ä½è¡€ç³–é¢¨éšª
  - å¤šç¨®å…¶ä»–è—¥ç‰©
- **ç‰¹æ®Šè­¦å‘Š**ï¼š
  - é›™å´è…å‹•è„ˆç‹¹çª„æ‚£è€…ç¦ç”¨
  - å–®åŠŸèƒ½è…åˆä½µè…å‹•è„ˆç‹¹çª„ç¦ç”¨
  - å­•å©¦ç¦ç”¨ (è‡´ç•¸é¢¨éšª)
  - è¡€ç®¡æ€§æ°´è…«é¢¨éšª


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Angioedema** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€è¡€æ “ã€è²§è¡€ã€‚

**å¿ƒè‡Ÿè¡°ç«­** ğŸŸ¢ Minor
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Diseases requiring hemodialysis** ğŸŸ¢ Minor
- æ³¨æ„äº‹é …ï¼šAnaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly wi...

**Hyperkalemia** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ä½è¡€å£“** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**é…’ç²¾** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚éœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚

**é«˜é‰€é£Ÿç‰©** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚å¯èƒ½æŠ‘åˆ¶è—¥ç‰©ä½œç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€é‰€ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚


## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**æ±ºç­–ï¼šHold**
**ç†ç”±ï¼š** TxGNN çš„é æ¸¬åœ¨è—¥ç†å­¸ä¸Šæœ‰éƒ¨åˆ†åˆç†æ€§ï¼Œä½†è‡¨åºŠå¯¦å‹™ä¸Šï¼Œè…è¡€ç®¡æ€§é«˜è¡€å£“ï¼ˆç‰¹åˆ¥æ˜¯é›™å´è…å‹•è„ˆç‹¹çª„ï¼‰æ˜¯ ACE æŠ‘åˆ¶åŠ‘çš„ç›¸å°ç¦å¿Œç—‡ã€‚æƒ¡æ€§é«˜è¡€å£“çš„æ²»ç™‚éœ€è¦å¿«é€Ÿä¸”å¯æ§çš„è¡€å£“ä¸‹é™ï¼Œé€šå¸¸ä½¿ç”¨éœè„ˆæ³¨å°„é™å£“è—¥ç‰©ã€‚æ­¤é æ¸¬å¯èƒ½åæ˜  ACE æŠ‘åˆ¶åŠ‘å°é«˜è¡€å£“ç›¸é—œè…ç—…çš„ä¸€èˆ¬æ€§æ•ˆç›Šï¼Œè€Œéç‰¹å®šé©æ‡‰ç—‡å»ºè­°ã€‚
**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
1. é‡æ¸…é æ¸¬çš„è‡¨åºŠæƒ…å¢ƒï¼šæ˜¯å¦æŒ‡è…è¡€ç®¡æ€§é«˜è¡€å£“çš„è¡“å¾Œæˆ–ä»‹å…¥å¾Œç®¡ç†ï¼Ÿ
2. æ’é™¤é›™å´è…å‹•è„ˆç‹¹çª„å¾Œï¼Œæ‰å¯è€ƒæ…®ä½¿ç”¨
3. æƒ¡æ€§é«˜è¡€å£“æ€¥æ€§æœŸæ‡‰ä½¿ç”¨éœè„ˆé™å£“è—¥ç‰©ï¼Œå¾…ç—…æƒ…ç©©å®šå¾Œå†è€ƒæ…®å£æœ ACE æŠ‘åˆ¶åŠ‘
4. æ­¤é æ¸¬ä¸å»ºè­°ç›´æ¥ç”¨æ–¼è‡¨åºŠæ±ºç­–

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Homatropine Methylbromide]({{ "/drugs/homatropine_methylbromide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Isoleucine]({{ "/drugs/isoleucine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alprostadil]({{ "/drugs/alprostadil/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tetrabenazine]({{ "/drugs/tetrabenazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ibuprofen]({{ "/drugs/ibuprofen/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Benazeprilè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/benazepril/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_benazepril,
  title = {Benazeprilè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/benazepril/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
